definiens: as used in this Section 3.07(a ) shall mean th at PROGENICS or its Affiliate or sublicensee hereunder has : ( a ) either 11 initiated a Phase I clinical trial or paid Mileston es 5 and 6 within three ( 3 ) years after delivery of the Sp2/0 Cell Line hereunder ; ( b ) either initiated a Phase II cli nical trial or paid Milestone 7 within six ( 6 ) year s after delivery of the Sp2/0 Cell Line hereunder ; and ( c ) either in itiated a Phase III clinical trial or paid Mileston e 8 within eight ( 8) years after delivery of the Sp2/0 Cell Line her eunder . PROGENICS shall provide PDL with regular, a nd in any event not less than annual, written summary rep orts of the development efforts on and progress of the Humanized Antibody and such further information as PDL may reasonably request in connection with any s uch written reports in order to establish satisfaction by PROGENICS of the condition to PDL ’s obligation u nder this Section 3.07